Metabolic · Body Composition
Cagrilintide
Also known as: AM833, NN9838
A long-acting amylin analog under Phase 3 investigation primarily in combination with semaglutide (CagriSema) for obesity and type 2 diabetes.
Sign in to add to watchlistEvidence strength
Strength of human clinical evidence — A (strongest) to D (mostly preclinical). This reflects research maturity, not safety or suitability.
Vial Theory provides educational research summaries only. Content is not medical advice, diagnosis, treatment, dosing guidance, or individualized suitability screening. Regulatory status can change over time and varies by jurisdiction.
Key Takeaways
- ›Cagrilintide is a long-acting amylin analog given once weekly; it is investigational, not approved.
- ›It is studied mainly in combination with semaglutide — a pairing called CagriSema — for obesity and type 2 diabetes.
- ›Early research showed the combination outperformed semaglutide alone, with Phase 3 trials ongoing.
- ›Nausea and other gastrointestinal effects are the most commonly reported side effects.
- ›It is not FDA-approved. Decisions about any weight-management therapy should involve a licensed healthcare professional.
What It Is
Cagrilintide is a synthetic long-acting analog of amylin, a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Native amylin contributes to glucose homeostasis through effects on gastric emptying, glucagon suppression, and central satiety pathways, and pramlintide (a synthetic short-acting amylin analog) has been FDA-approved for type 1 and type 2 diabetes since 2005.
Cagrilintide was developed by Novo Nordisk with structural modifications that extend the plasma half-life to support once-weekly subcutaneous administration, in contrast to pramlintide's multiple-daily-dose profile. Mechanistically, amylin acts at the amylin receptor (a heterodimer of the calcitonin receptor and receptor activity-modifying proteins) and has been characterized as complementary to GLP-1 in producing satiety and metabolic effects through partly distinct central and peripheral mechanisms.
Unlock the full Cagrilintide research report
Vial+ opens the mechanism breakdown, evidence graphs, potential benefits, safety considerations, regulatory status, a plain-language explainer, and 3 cited sources.
Get Vial+ — $20 one-timeLifetime access · the community forum stays free.
Disclaimer: This content is for educational and research purposes only and is not medical advice. Always consult a licensed healthcare professional before making health-related decisions.